soblidotin

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Mol. weight
701.99 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • auristatin pe
  • auristatin pe
  • n(2)-(n,n-dimethyl-valyl)-n-(2-methoxy-4-(2-(1-methoxy-2-methyl-3-oxo-3-((2-phenylethyl)amino)propyl)-1-pyrrolidinyl)-1-(1-methylpropyl)-4-oxobutyl)-n-methyl-valinamide
  • soblidotin
  • soblidotin
  • soblidotin
  • soblidotin
  • soblidotin
  • tzt 1027
  • tzt-1027

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00072228Phase 1Nov 4, 2003Daiichi
NCT00061854Phase 2Apr 1, 2003Daiichi, Daiichi Sankyo
NCT00064220Phase 2Apr 1, 2003Daiichi Sankyo, National Cancer Institute (NCI)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
DaiichiFor profit2122003
Daiichi SankyoFor profit2212003
National Cancer Institute (NCI)Government1012003
3 organizations
Page 1 / 1